Abstract Keratoacanthoma is a tumor that is seen on a regular basis in a dermatologic and dermato-oncologic practice. The accurate management of this tumor is the biggest challenge. Many treatment options are available. In this review, we summarize the clinical and histological features of this not uncommon tumor. We review the current management with an emphasis on treatment.
Introduction
Since it was first described in 1889 by Hutchinson [1] and recognized as an entity in the 1950s, keratoacanthoma (KA) has always been a conundrum. The diagnosis of this tumor is always easy to make retrospectively, but clinically it is always a challenge and the clinician must be careful because KA may not behave like one.
Making the Diagnosis
Keratoacanthoma is a cutaneous tumor that affects elderly patients (commonly in hair-bearing regions and central part of the face) but also middle-aged patients. They often develop on chronic sun-exposed skin but may appear on nonoverexposed skin. They have not been reported on the palms and soles, or mucous surfaces. This tumor erupts rapidly over a few to several weeks. There is a rapid growth (4-6 weeks) and KA can reach 2 cm within a couple of months. It is capable of auto-resolution. This last point is essential for the diagnosis of this tumor. The clinical regression frequently observed in KA is also an important feature [2••] . It is improbable that invasive squamous cell carcinoma will involute by itself, but this can be established only retrospectively. There has been an ongoing debate since it was first described as to whether keratoacanthoma is or is not a distinct subset of well-differentiated squamous cell carcinoma (SCC) [1, 2••, 3-8, 9 ••]. Some KA has been reported to metastasize, but this unexpected evolution of KA may be the consequence of a SCC that was initially misdiagnosed [7] .
The clinical aspect of KA is the other key point. The first evidence of KA is a well-defined, rounded, firmed papule, plaque, or nodule that is flesh colored or reddish. When it was first described, a yellowish aspect was described and it was termed molluscum sebaceum [10] . The epidermis over the nodule is shiny and numerous telangiectasias can be seen just under the surface. The center is made of a keratin-filled crater and may be covered by a crust. Table 1 summarizes the clinical differences between KA and SCC There are many clinical variants of solitary KA. Two forms, giant keratoacanthoma (GKA) and keratoacanthoma centrifugum marginatum (KACM) [11•] , may attain a large size. Those lesions may grow rapidly and reach a size from 5 cm up to 20 cm. In GKA, involution occurs after several months, whereas with KACM there is no tendency toward spontaneous regression. Another variant is subunguial and can be seen on the distal portion of a fingernail. This entity rarely shows spontaneous involution.
Others clinical sub-types are worth mentioning. Multiple self-healing squamous epitheliomas (Ferguson-Smith syndrome) were described in 1930. It is a rare autosomal dominant condition where multiple keratoacanthomas develop. A mutation in the TGFBR1 gene in these patients has been reported [12] . Multiple lesions have also occurred in patients with defective cell-mediated immunity. KA is also a feature of Torre's syndrome, with multiple internal malignancies associated with sebaceous adenoma. Another entity, generalized eruptive keratoacanthoma [13] , has also been reported. It particularly affects the face, and the lesions can be confluent. Spontaneous involution of lesions is the rule for this sub-type.
On dermoscopy, classic KA may show an unspecific pattern with a central ulceration with blood crusts. On classical cases, a corona of elongated hairpin blood vessels on a white background corresponding to a white keratotic halo can be seen. Other dermoscopic features of keratoacanthomas are multicomponent pattern, polymorphous vessel, and central keratotic plug. Unfortunately, elongated hairpin blood vessels on a white keratotic halo are non-specific of keratoacanthomas and can be observed in invasive squamous cell carcinomas [14] . In summary, dermoscopy is helpful to comfort ourselves for classical cases where classical clinical features are also present.
Histology and Pathogenesis
Histologically, the characteristics of KA can be very similar to a well-differentiated SCC [2••, 9••]. The tumor has a symmetrical globular form and is localized in the dermis. Usually, the extension is not deeper than the sweat glands. The epidermis becomes thinned as it rises over the tumor. Absence of actinic keratosis surrounding the tumor is often observed. Centrally, a crateriform squamous proliferation with a central core of compact hyperkeratotic is seen [5] . Atypia and atypical mitotic figures can also be seen but are usually limited. Keratinocytes may show glassy and eosinophilic cytoplasm. Neutrophil micro-abscess may be present and is a helpful feature.
Because of the overlap of KA and SCC features, it is a challenge for dermatopathologists to establish diagnosis without any doubt. Regularly, an overlap diagnosis is made ("SCC with KA-like properties" or "KA but invasive SCC cannot be ruled out") and makes treatment decisions difficult. Table 2 summarizes the histologic features of KA.
The pathogenesis is still unclear. It is known that lesions start with hyperplasia of the infundibulum of one or many follicles, but cause is not known. Some studies explored the theory of viral genesis. Some of them found a link between the tumor and HPV sub-types [15] , but more studies are needed as results are inconsistent [16] .
Management
KA are well known for their rapid rate of growth but this is also seen with SCC, especially in immunosuppressed patients. Because of spontaneous involution seen in classical cases, a conservative "wait and see" approach after a clear histopathologic diagnosis theoretically could be done. This involution usually happens after 6 months or so [2••] . But because squamous cell carcinoma can masquerade as KA, caution is imperative. Also, because many modalities are available and can be easily performed, it is the rule to offer an active management. Another reason to treat is that regression of KA causes important scarring.
Surgical treatment is the gold standard for KA management. Standard surgical excision [3, 4] in the region can be easily done should be performed. If standard excision for KA is the option, it is logical to use the currently recommended surgical margins for SCC (4-6 mm) [17] . Curettage and electrodessication [18, 19] is also an interesting modality but the tumor may recur. Mohs surgery is the treatment of choice when tissue sparing is an issue [20] . Also, in solid organ transplant patients (SOTP), KA should be treated by Mohs for two reasons. First, because of high risk of recurrence. The other reason involves the problem of making an accurate diagnosis when a biopsy is performed on KA. In our experience, histological diagnosis of KA is seldom done in SOTP. The histologic features are usually in favor of SCC and treatment is performed consequently. Many other treatments have been described. Systemic retinoids [21] may be useful in some situations and could be used in multiple lesions. Intralesional therapies such as intra-lesional methotrexate (IL-MTX) [22] [23] [24] [25] [26] [27] [28] 29 ••] and 5-fluorouracil [22, 30] have been used for solitary lesions with various success rates and side effects. In our center we examined retrospectively 46 patients who were treated with IL-MTX [29••] . A complete resolution was achieved in 74 % of patients, requiring an average of 1 to 8 injection sessions. Mean total dosage was 10 mg. In this study, we used a 3-cc syringe (25-G needle) and a MTX concentration of 25 mg/mL, which was diluted 1/2:1/2 using in most cases xylocaine 1 % with epinephrine or normal saline in some patients. Xylocaine 1 % with epinephrine is of interest for injection by blanching the lesion and showing presence of the product. Figure 1 demonstrates the technique of injection. IL-MTX is an interesting option for classic KA because it is minimally invasive, well tolerated, and barely leaves a visible scar. Close follow-up (every 2-4 weeks) is mandatory so tumor involution may be assessed. Previous case reports conclude that IL-MTX is an effective treatment for some selected KA as well as a minimally invasive procedure [22, 29••] . Surgical management should be undergone immediately if there is no response to IL-MTX and the physician must be ready to act accordingly. Other treatment options are rarely used and include radiation [31] and topical imiquimod [32] . Table 3 shows treatment options for KA.
Over the past few years, case reports showed eruption of KA as a surgical complication [33, 34] . It may occur on or surrounding previous surgical sites but also at a distant site [35] . Etiology of this phenomenon is obscured. As trauma of the skin is involved in all cases, the hypothesis of viral infection of keratinocytes could be raised and support the viral genesis pathway in this tumor.
Conclusions
Because of its unforeseeable evolution, keratoacanthoma is a challenging tumor. In the past when accessibility to medical care was difficult, many of these tumors did probably regress without treatment. But in our era, with all possibilities of 
